Jeff Yass’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Jeff Yass’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-19,161	Closed	-$7K	–	10209
2015 Q4	$7K	Buy	+19,161	New	+$9.08K	﹤0.01%	9314
2015 Q3	–	Sell	-2,453,100	Closed	-$1.32M	–	10709
2015 Q2	$1.32M	Buy	+2,453,100	New	+$2M	﹤0.01%	5587
2015 Q1	–	Sell	-29,277	Closed	-$23K	–	10379
2014 Q4	$23K	Buy	+29,277	New	+$26.8K	﹤0.01%	9476

Other funds holding PVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Jeff Yass's PVCT Position: Q1 2016 in Review

Jeff Yass sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q1 2016, closing a stake of 19,161 shares — an estimated $7K sold.

Jeff Yass first reported a position in PVCT in Q4 2014 and held it in 3 quarters. The position peaked at $1.32M in Q2 2015. 44 funds tracked by Wall St. Rank hold PVCT as of Q1 2016.

Jeff Yass reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q1 2016 after selling out during the quarter.
Jeff Yass sold 19,161 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q1 2016, an estimated $7K.
Jeff Yass first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2014 and held it in 3 quarters.
Jeff Yass's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $1.32M in Q2 2015.
44 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q1 2016.

Based on Susquehanna International Group's 13F filing for Q1 2016, filed 13 May 2016.